Michael Weiss
Neurology · Seattle, WANPI 1639269582
Payments from drug & device makers
Across 216 payments — averaging $4334.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$304K
- Orion Corporation$144K
- Novartis$118K
- Mitsubishi Tanabe Pharma Development America, Inc.$101K
- Argenx US, Inc.$67K
- Tanabe Pharma America, Inc.$50K
- plus $152K from 15 others
Across 1 payment — averaging $3540.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB, Inc.$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 26 | $304,427 |
| Orion Corporation | 11 | $144,485 |
| Novartis | 1 | $118,003 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 6 | $100,704 |
| Argenx US, Inc. | 26 | $66,825 |
| Tanabe Pharma America, Inc. | 28 | $49,787 |
| UCB, Inc. | 40 | $36,193 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $35,208 |
| AstraZeneca | 10 | $31,088 |
| Amgen | 18 | $14,213 |
| Biogen | 10 | $12,092 |
| Amylyx Pharmaceuticals, Inc. | 1 | $9,283 |
| Catalyst Pharmaceuticals, Inc. | 1 | $3,780 |
| UCB Biosciences Inc. | 1 | $2,500 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $2,447 |
| Sanofi US Services Inc. | 2 | $2,440 |
| Sanofi | 1 | $1,830 |
| CSL Behring | 2 | $263 |
| Grifols Shared Services North America, Inc. | 3 | $215 |
| Janssen Scientific Affairs, LLC | 2 | $197 |
| Cadwell Industries, Inc | 1 | $170 |
How this compares
$936,149 in reported general payments places this provider in the 95th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Seattle
- Pavle RepovicSeattle$4.8M
- Michael RosenbloomSeattle$1.8M
- Suman JayadevSeattle$740K
- Lucas McCarthySeattle$734K
- Annette WundesSeattle$625K
- Christyn EdmundsonSeattle$614K
- Nathaniel WatsonSeattle$496K
- Gloria von GeldernSeattle$441K
- Pravin KhemaniSeattle$431K
- Leo WangSeattle$362K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.